AI Verdict
KAPA has stronger fundamentals based on our AI analysis.
KARX vs KAPA Fundamental Comparison
| Metric | KARX | KAPA |
|---|---|---|
| Revenue | $56.5M | N/A |
| Net Income | $-4.0M | $-5.4M |
| Net Margin | -7.2% | N/A |
| ROE | N/A | -85.9% |
| ROA | -21.9% | -83.3% |
| Current Ratio | 1.15x | 27.07x |
| Debt/Equity | N/A | 0.00x |
| EPS | $-0.05 | $-0.30 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
KARX vs KAPA: Frequently Asked Questions
Is KARX or KAPA a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), KAPA has stronger fundamentals. KARX is rated STRONG SELL (97% confidence) while KAPA is rated SELL (85% confidence). This is not investment advice.
How does KARX compare to KAPA fundamentally?
Karbon-X Corp. has ROE of N/A vs Kairos Pharma, LTD.'s -85.9%. Net margins are -7.2% vs N/A respectively.
Which stock pays higher dividends, KARX or KAPA?
KARX has a dividend yield of N/A or no dividend while KAPA has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in KARX or KAPA for long term?
For long-term investing, consider that KARX has STRONG SELL rating with 97% confidence, while KAPA has SELL rating with 85% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about KARX vs KAPA?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For KARX vs KAPA, the AI consensus favors KAPA based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.